证券代码：600594 证券简称：益佰制药 公告编号：2023-009 贵州益佰制药股份有限公司 关于参加"2022 年度贵州辖区上市公司业绩说明会暨投资 者集体接待日活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 17 日 星期三 15：30-17：00 会议召开方式：本次"2022 年度贵州辖区上市公司业绩说明会暨投资者集 体接待日活动"（以下简称"业绩说明会"）将采用网络互动方式举办，投资者 可以登录"全景路演"（网址：http://re.p5w.net）在线参与。 投资者即日起可通过微信关注"贵州资本市场"公众号，发送关键词"提 问"即可进入专区提前提问，提问通道自本公告发出之日起开放至 2023 年 5 月 15 日 17：00 截止，贵州益佰制药股份有限公司（以下简称"公司"）将在业绩说 明会上对投资者普遍关注的问题进行回答。 为促进上市公司规范运作、健康发展，增加上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，在贵州证 ...

Financial Performance - The company reported a distributable profit of ¥1,219,402,212.32 as of December 31, 2022, with the parent company's distributable profit at ¥149,802,347.15[6] - The board of directors decided not to distribute profits or increase capital reserves for the year 2022, considering industry development and operational needs[6] - The company's operating revenue for 2022 was approximately ¥2.74 billion, a decrease of 18.27% compared to ¥3.35 billion in 2021[24] - The net profit attributable to shareholders for 2022 was approximately -¥467.86 million, a decline of 351.65% from ¥185.92 million in 2021[24] - The basic earnings per share for 2022 was -¥0.539, down 275.00% from ¥0.308 in 2021[25] - The weighted average return on equity decreased to -12.963% in 2022, down 20.166 percentage points from 7.203% in 2021[25] - The net cash flow from operating activities for 2022 was approximately ¥345.30 million, a decrease of 63.04% from ¥934.21 million in 2021[24] - The total assets at the end of 2022 were approximately ¥4.87 billion, a decrease of 3.99% from ¥5.07 billion at the end of 2021[24] - The net assets attributable to shareholders decreased to approximately ¥3.04 billion at the end of 2022, down 13.10% from ¥3.50 billion at the end of 2021[24] - The company reported a significant increase in goodwill impairment provisions, contributing to the decline in net profit[26] Audit and Compliance - The company has received a standard unqualified audit opinion from Zhongzheng Tiantong Accounting Firm[5] - The company’s financial report has been declared true, accurate, and complete by its responsible persons[6] - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8] - The company has not violated decision-making procedures for external guarantees[8] - The company held three shareholder meetings during the reporting period, ensuring compliance with legal and procedural requirements[183] - The controlling shareholder has not interfered with the company's decision-making or operations, maintaining independence in business and financial matters[184] - The board of directors operates independently, with committees established to ensure compliance and effective governance[185] - The company published 34 interim announcements and 4 periodic reports, emphasizing transparency and timely information disclosure[189] - The company is committed to improving corporate governance and risk management to protect investor rights and ensure compliance[192] Research and Development - The company is focusing on innovation and R&D, with ongoing projects including the production research of Pearl Droplets and the registration of YBY-6002 and Plasmapheresis Injection[44] - The company has established a comprehensive R&D system, integrating drug research institutes and engineering centers to enhance innovation capabilities[44] - The company has applied for a total of 510 patents, with 217 patents authorized and maintained as valid, and 55 patents under review[89] - The company has initiated clinical research for YBR-6005 and YBR-8002, both classified as category 4 drugs[140] - The company reported a significant increase in R&D investment for YBR-6002, with a 780.80% increase compared to the previous year[154] - The R&D investment capitalized ratio is 0%, indicating all R&D expenses were expensed in the current period[152] - The company’s R&D investment as a percentage of net assets is 4.17%[152] - R&D investment accounted for 4.64% of operating income, with a total R&D expenditure of approximately 1.2 billion RMB[152] Market and Industry Trends - The pharmaceutical industrial segment contributed 83.08% of total revenue, while the medical services segment accounted for 16.70%[38] - The national policies supporting the pharmaceutical industry, such as the "14th Five-Year Plan," are expected to create new opportunities and challenges for the company[36] - In 2022, the pharmaceutical manufacturing industry in China achieved a revenue of CNY 2,911.14 billion, a year-on-year decrease of 1.6%[53] - The total profit for the pharmaceutical manufacturing sector was CNY 428.87 billion, down 31.8% year-on-year[53] - The total operating costs for the industry reached CNY 1,698.46 billion, reflecting a year-on-year increase of 7.8%[53] - The healthcare service industry is expected to grow rapidly due to rising healthcare spending willingness and an aging population[56] - The Chinese traditional medicine market size reached 75.3 billion yuan in 2021, with a compound annual growth rate of 3.1% from 2017 to 2020[54] - The number of visits to private medical institutions increased by 3.1% year-on-year, indicating significant progress in healthcare reform[56] Production and Operations - The company is advancing the construction of the new factory project at Meian Technology New City, which has completed and is undergoing trial production[48] - The company is enhancing its production lines for chemical injections and lyophilized preparations to improve product quality and capacity[48] - The company has completed the transformation of its subsidiary's comprehensive workshop and obtained ISO14001 environmental management certification[47] - The company is committed to digital transformation to enhance competitiveness and contribute to the digital economy[46] - The company is implementing a lean production management model to improve production technology levels and ensure compliance with regulatory requirements[172] - The company is advancing the production line renovation for chemical drug injections and freeze-dried preparations to release production capacity and improve product quality[172] Sales and Marketing - The company is actively expanding its market presence through a multi-structure and multi-level marketing strategy, focusing on core product teams and enhancing terminal market management[45] - The company has established a comprehensive marketing system to cover hospital institutions, retail pharmacies, and third-party terminals nationwide[156] - The sales strategy is market demand-driven, focusing on customer service and optimizing sales policies to enhance product reach and market penetration[80] - The company aims to improve the talent development system for traditional Chinese medicine, with a target of a more comprehensive talent structure by 2025[70] - The company is focusing on building a digital supply chain management system to enhance real-time monitoring and efficiency across the production and sales processes[173] Challenges and Risks - The company is facing risks related to R&D, quality control, industry regulation, and macroeconomic changes, which could impact operational performance and product demand[175][176][178] - The company has faced risks from natural disasters and public health emergencies that could impact normal operations[180] - The company is actively addressing challenges in the traditional Chinese medicine sector through regulatory improvements and innovation encouragement[71] Corporate Governance - The company is actively improving its corporate governance mechanisms to protect investor rights and enhance shareholder returns[49] - The company plans to implement a three-year shareholder return plan from 2022 to 2024[197] - The company has proposed to revise several internal governance documents, including the Articles of Association and the rules for shareholder meetings[197] - The company’s independent directors received a total compensation of 6.00 million yuan each for the reporting period[197] - The company’s management team has extensive experience in the pharmaceutical industry, with key members holding significant positions in various related companies[199]

2023 年第一季度报告 证券代码：600594 证券简称：益佰制药 贵州益佰制药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度(%) | | | | --- | --- | --- | --- | --- | | 营业收入 | 683,797,926.88 | | | -0.59 | | 归属于上市公司股东的净利润 | 43,999,942.75 | | | -12.96 | | 归属于上市公司股东的扣除非经常 性损益的净利润 | 31,811,1 ...

公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 2022 年第三季度报告 证券代码：600594 证券简称：益佰制药 贵州益佰制药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | | 增减变动幅度 | | | | | | (%) | | 营业收入 | 653,147,887.70 | -28.90 | 2,099,211,303.23 | -19.44 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,446,063,415.53, a decrease of 14.29% compared to CNY 1,687,093,513.37 in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2022 was CNY 126,841,647.60, down 25.85% from CNY 171,069,100.74 in the previous year[20]. - The net cash flow from operating activities decreased by 72.52%, amounting to CNY 114,708,370.37 compared to CNY 417,460,566.61 in the same period last year[20]. - Basic earnings per share for the first half of 2022 were CNY 0.160, a decrease of 25.93% from CNY 0.216 in the same period last year[21]. - The weighted average return on net assets decreased by 1.402 percentage points to 3.556% compared to 4.958% in the previous year[21]. - The company achieved a total revenue of 1,446.06 million yuan and a net profit attributable to shareholders of 126.84 million yuan in the first half of 2022[52]. - The total profit for the first half of 2022 was CNY 150.30 million, a decrease of 26.39% compared to CNY 204.10 million in the same period of 2021[150]. - The company's total comprehensive income for the first half of 2022 was CNY 125.82 million, compared to CNY 163.99 million in the first half of 2021, reflecting a decrease of 23.25%[148]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,816,583,367.68, an increase of 14.77% from CNY 5,068,038,586.32 at the end of the previous year[20]. - The total assets of the company as of June 30, 2022, reached RMB 5,816,583,367.68, an increase from RMB 5,068,038,586.32 at the beginning of the period, reflecting a growth of approximately 14.76%[139]. - Total liabilities reached CNY 1,730,727,760.79, an increase of 29.3% compared to CNY 1,338,665,179.44 at the start of the year[144]. - The company's total liabilities at the end of the reporting period were CNY 1.77 billion, which is a slight increase from CNY 1.77 billion in the previous year[166]. Research and Development - The company is committed to enhancing its core competitiveness through innovation in research and development, production technology, sales, and management[34]. - The company has established a cardiovascular research center and is actively developing products like the pearl drop pill, enhancing its product line[57]. - Research and development expenses for the first half of 2022 were CNY 52,010,184.72, down 17.7% from CNY 63,232,375.06 in the previous year[146]. - The company is focusing on developing health products and special medical purpose formula foods, increasing R&D investment in the health sector[56]. Market and Industry Trends - The pharmaceutical industry in China is expected to continue expanding due to increasing healthcare demands driven by an aging population and rising living standards[36]. - In 2021, the total revenue of China's pharmaceutical manufacturing industry reached CNY 2,928.85 billion, a year-on-year increase of 20.1%, with total profits of CNY 627.14 billion, up 77.9%[37]. - In the first half of 2022, the pharmaceutical manufacturing industry achieved operating income of CNY 1,400.78 billion, a year-on-year decrease of 0.6%, and total profits of CNY 220.95 billion, down 27.6%[39]. Corporate Governance and Compliance - The company emphasizes a procurement model that reduces costs while ensuring quality through a centralized purchasing platform[29]. - The company has not disclosed any new equity incentive plans or employee stock ownership plans during the reporting period[91]. - The company is committed to maintaining transparency in its governance and compliance with legal regulations[89]. - The company has established an environmental self-monitoring plan in compliance with relevant regulations, which has been submitted for review and is monitored by a third-party testing agency[106]. Environmental Responsibility - The company is committed to the principles of circular economy and environmental protection in its operations[99]. - The company has established a wastewater treatment facility with a capacity of 2,000 m³/d, while subsidiaries have smaller facilities of 50 m³/d and 120 m³/d[98]. - The company has implemented measures to reduce carbon emissions, including upgrades to the exhaust collection systems and end-treatment facilities[113]. - The company has received 43 international trademark registrations, with 34 currently valid, enhancing its brand recognition[46]. Strategic Focus and Future Outlook - The company is focusing on expanding its healthcare and wellness sectors as part of its "one ship, two wings" strategy[34]. - The company plans to adjust its prescription drug sales structure to a provincial responsibility system to adapt to the normalized procurement environment[66]. - The company plans to focus on expanding its market presence and investing in new product development to drive future growth[162]. - The company is exploring high-quality external acquisitions and new product opportunities to enhance profitability and investment returns[70].

证券代码：600594 证券简称：益佰制药 公告编号：2022-012 贵州益佰制药股份有限公司 关于参加"2021 年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2022 年 5 月 13 日 星期五 09:30-11:30 会议召开方式：本次"2021 年度贵州辖区上市公司业绩说明会暨投资者 集体接待日活动"（以下简称"业绩说明会"）将采用网络互动方式举办，投资 者可以登录"全景路演"（网址：http://rs.p5w.net）在线参与。 投 资 者 即 日 起 可 访 问 全 景 网 投 资 者 关 系 互 动 平 台 （ 网 址 ： http://ir.p5w.net/zj/），进入问题征集专题页面提交问题。贵州益佰制药股 份有限公司（以下简称"公司"）将在业绩说明会上对投资者普遍关注的问题进 行回答。 为促进上市公司规范运作、健康发展，增加上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平， ...

Financial Performance - In 2021, the net profit attributable to shareholders of Guizhou Yibai Pharmaceutical Co., Ltd. was CNY 243,772,727.54, with no profit distribution or capital reserve transfer planned for the year[6]. - The company's operating revenue for 2021 was CNY 3,346,704,605.71, a decrease of 1.95% compared to CNY 3,413,192,886.11 in 2020[27]. - Net profit attributable to shareholders was CNY 243,772,727.54, representing a growth of 6.56% from CNY 228,757,143.09 in the previous year[27]. - The cash flow from operating activities increased significantly by 154.79% to CNY 934,211,133.02 from CNY 366,657,366.28 in 2020[27]. - Basic earnings per share rose to CNY 0.308, a 6.57% increase from CNY 0.289 in 2020[28]. - The weighted average return on equity increased to 7.203%, up by 0.143 percentage points from 7.060% in the previous year[28]. - Total assets decreased by 3.03% to CNY 5,068,038,586.32 from CNY 5,226,386,677.52 at the end of 2020[27]. - The company reported a net profit of CNY 70,987,858.89 in Q1 2021, which decreased to a loss of CNY 53,348,958.72 in Q4 2021[31]. - Non-recurring gains and losses amounted to CNY 57,855,236.76 for the year, compared to CNY 40,393,124.68 in 2020[33]. Risk Management - There were no significant risks that materially affected the company's production and operations during the reporting period[10]. - The company has outlined various risks and countermeasures in its management discussion and analysis section[10]. - The company faces risks from industry regulations and market changes, necessitating an agile response to policy shifts and competitive pressures[122]. Governance and Compliance - The company has maintained a standard unqualified audit report from Zhongzheng Tiantong Accounting Firm[5]. - The board of directors and supervisory board members confirmed the authenticity, accuracy, and completeness of the annual report[5]. - The company has not provided guarantees in violation of regulatory decision-making procedures[8]. - There were no instances where more than half of the directors could not guarantee the authenticity of the disclosed annual report[9]. - The company is committed to improving its governance mechanisms and investor protection measures, ensuring compliance with evolving regulations[43]. - The internal control system is aligned with regulatory guidelines, with the audit committee holding 4 meetings to oversee compliance and effectiveness[130]. - The company has actively engaged in self-inspection activities related to corporate governance, revising relevant internal regulations[165]. Research and Development - The company is focusing on innovation and R&D, with significant investments in developing new drugs and enhancing existing products, achieving 62 product re-registrations during the reporting period[41]. - The company plans to enhance its R&D efforts in response to market demands while maintaining product quality control[49]. - The company aims to increase innovation investment and enhance R&D efficiency by developing more characteristic traditional Chinese medicine varieties[97]. - The company has sufficient technical and financial resources to support the development of intangible assets related to R&D[104]. - The company’s total R&D investment reached RMB 4,070 million, accounting for 4.07% of operating revenue and 3.88% of net assets[106]. Market Expansion and Strategy - The company anticipates continued growth in the pharmaceutical market driven by increasing healthcare demands and supportive government policies[36]. - The company is positioned to leverage opportunities arising from ongoing healthcare reforms and the aging population in China[36]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[140]. - The company aims to improve its product line and production quality through the new factory, which will support the development of chemical drug generics and enhance production processes[43]. - The company is committed to improving profitability through internal growth and high-quality external mergers and acquisitions, optimizing medical assets like hospitals[121]. Environmental Management - The company is committed to sustainable development and has increased environmental protection investments to meet rising regulatory standards[126]. - The company has established wastewater treatment facilities with a capacity of 2000m³/d, and its subsidiaries have additional capacities of 50m³/d and 120m³/d respectively[172]. - The company has implemented a solid waste management system, with ordinary solid waste and hazardous waste being handled by designated service providers[171]. - The company has achieved compliance with wastewater, waste gas, and noise emissions through third-party monitoring[195]. - The company has established an environmental self-monitoring plan in compliance with the pollution discharge permit[184]. Employee and Talent Development - The company emphasizes a talent development strategy, focusing on both professional skills and overall employee quality improvement through targeted training programs[154]. - The company has a structured salary system aimed at enhancing work efficiency and product quality, with different compensation models for management, sales, and production staff[153]. - The company reported a total of 6,161 employees, with 2,656 in the parent company and 3,505 in major subsidiaries[152]. Shareholder Engagement - The company has held 2 shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[127]. - The company has published 41 interim announcements, demonstrating a commitment to transparency and timely information disclosure[129]. - The company distributed a cash dividend of 0.13 yuan per share (including tax), totaling 102,950,562.00 yuan to all shareholders[200].

Financial Performance - The company's operating revenue for Q1 2022 was ¥687,874,165.98, representing a decrease of 16.60% compared to the same period last year[3]. - The net profit attributable to shareholders was ¥50,549,194.35, down 28.79% year-on-year[3]. - The basic earnings per share for the period was ¥0.064, reflecting a decline of 28.89% year-on-year[3]. - Net profit for Q1 2022 was ¥49.07 million, a decline of 27.0% from ¥67.13 million in Q1 2021[18]. - Operating profit for Q1 2022 was ¥70.93 million, a decrease of 13.6% compared to ¥82.08 million in Q1 2021[18]. - Total operating revenue for Q1 2022 was ¥687.87 million, a decrease of 16.6% compared to ¥824.81 million in Q1 2021[17]. - Total operating costs for Q1 2022 were ¥623.41 million, down 16.7% from ¥747.88 million in Q1 2021[17]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 87.25%, amounting to ¥52,616,988.53, primarily due to reduced collections and discounts[6]. - Cash flow from operating activities for Q1 2022 was ¥52.62 million, down 87.3% from ¥412.83 million in Q1 2021[22]. - Cash flow from investing activities for Q1 2022 was -¥64.08 million, compared to -¥0.17 million in Q1 2021[22]. - Cash flow from financing activities for Q1 2022 was ¥93.17 million, an improvement from -¥24.11 million in Q1 2021[22]. - The beginning balance of cash and cash equivalents was 378.97 million, while the ending balance reached 460.67 million[23]. - Cash and cash equivalents rose to RMB 460,672,126.35, up from RMB 379,628,229.16, indicating an increase of about 21.4%[13]. - Total current assets increased to RMB 1,929,709,096.81 from RMB 1,725,840,439.71 at the end of 2021, reflecting a growth of approximately 11.8%[14]. - The company's total assets reached RMB 5,263,876,579.34, up from RMB 5,073,897,321.50, reflecting a growth of approximately 3.7%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 63,298[8]. - The largest shareholder, Dou Qiling, holds 23.42% of the shares, with 137,988,740 shares pledged[8]. - The company's total equity attributable to shareholders was ¥3,553,794,319.42, an increase of 1.44% from the previous year[4]. - The equity attributable to shareholders increased to RMB 3,553,794,319.42 from RMB 3,503,200,304.50, showing an increase of about 1.4%[16]. Expenses and Liabilities - Research and development expenses for Q1 2022 were ¥20.54 million, a decrease of 28.0% from ¥28.52 million in Q1 2021[17]. - Sales expenses for Q1 2022 were ¥331.70 million, down 23.5% from ¥434.12 million in Q1 2021[17]. - Total liabilities as of March 31, 2022, amounted to RMB 1,652,309,829.62, compared to RMB 1,511,445,364.60 at the end of 2021, marking an increase of about 9.3%[15]. Investments and Projects - Guizhou Yibai Pharmaceutical's subsidiary Yibai Investment acquired 20% equity of Aide Pharmaceutical for RMB 14 million, aiming for 100% ownership after the transaction completion[10]. - The company sold 19.975% equity of Kangde Pharmaceutical for RMB 10,000, with the transaction currently in the process of equity change registration[11]. - The new factory project of Chang'an Pharmaceutical has reached 94% completion, with major equipment currently undergoing debugging[12]. Accounting Standards - The company is not applying the new accounting standards for the year 2022[23].

2021 年第三季度报告 证券代码：600594 证券简称：益佰制药 贵州益佰制药股份有限公司 2021 年第三季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | 单位：元 币种：人民币 | | --- | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 918,651,705.01 | -4.35 | 2,605,745 ...

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥1,687,093,513.37, representing a 14.54% increase compared to ¥1,472,885,408.15 in the same period last year[18]. - Net profit attributable to shareholders was ¥171,069,100.74, up 41.37% from ¥121,012,070.44 in the previous year[19]. - The net cash flow from operating activities increased by 67.18% to ¥417,460,566.61, compared to ¥249,707,137.91 in the same period last year[19]. - The company reported a net profit excluding non-recurring gains and losses of ¥153,680,921.78, which is a 31.84% increase from ¥116,570,478.20 in the same period last year[19]. - Basic earnings per share increased by 41.18% to CNY 0.216 compared to the same period last year[20]. - Diluted earnings per share also rose by 41.18% to CNY 0.216 year-on-year[20]. - The weighted average return on equity increased by 1.653 percentage points to 4.958%[20]. - The company achieved operating revenue of 168,709.35 million yuan, a year-on-year increase of 14.54% compared to 147,288.54 million yuan in the same period last year[40]. - Net profit attributable to shareholders reached 17,106.91 million yuan, reflecting a growth of 41.37% year-on-year[40]. - The total profit for the first half of 2021 was approximately ¥101 million, an increase of 30.96% from ¥77 million in the same period of 2020[128]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,254,817,332.09, reflecting a 0.54% increase from ¥5,226,386,677.52 at the end of the previous year[19]. - The company's equity attributable to shareholders increased to CNY 3,433,656,321.49 from CNY 3,365,164,558.12, reflecting a growth of approximately 2.02%[119]. - Current assets decreased to CNY 2,217,445,169.01 from CNY 2,284,178,417.96, a decline of approximately 2.93%[118]. - Total liabilities decreased to CNY 1,754,337,647.09 from CNY 1,763,260,831.85, a reduction of approximately 0.29%[119]. - Short-term borrowings reduced significantly to CNY 563,553,000.00 from CNY 745,553,000.00, a decrease of about 24.4%[119]. - The total assets decreased to ¥3,909,859,881.24 from ¥4,077,819,077.72, a decline of 4.1%[123]. - Total liabilities decreased to ¥1,378,560,167.91 from ¥1,530,010,853.16, a reduction of 9.9%[123]. Research and Development - The company is focusing on R&D for new drugs, including chemical generics and innovative drugs, to ensure sustainable development[41]. - The company is committed to developing health products, including special medical purpose formula foods, and is increasing R&D investment in this area[43]. - Research and development expenses for the first half of 2021 were ¥63,232,375.06, slightly up from ¥60,586,657.08 in the previous year[125]. - The company plans to enhance R&D efficiency and increase investment in R&D to mitigate risks associated with drug development, which is characterized by high investment, high risk, and high return[66]. Market Strategy and Operations - The company is transitioning from a modern traditional Chinese medicine manufacturer to a comprehensive pharmaceutical enterprise with chemical drugs and biological drugs[28]. - The company aims to enhance its product structure and expand its market share in the health product sector, focusing on special medical purpose formula foods[28]. - The company has established a group procurement platform to reduce procurement costs and improve quality control[26]. - The sales strategy includes a focus on direct sales and a specialized marketing approach to enhance market penetration[26]. - The company is committed to improving production management and cost control to enhance product profitability[28]. - The company is enhancing its marketing strategies to align with its extensive product line, aiming for increased sales growth[41]. Environmental and Regulatory Compliance - The company has been recognized as a national-level innovative enterprise and has received support for its research and development initiatives[33]. - Environmental policy compliance is crucial for the company, as increased environmental protection requirements may lead to higher operational costs[69]. - The company has established a wastewater treatment plant with a capacity of 2000m³/d, and a stable operation has been reported[82]. - The company has implemented a self-monitoring plan for environmental protection, with all pollutant indicators meeting discharge standards[85]. - The company has enhanced its environmental management system to ensure compliance with national standards and timely payment of relevant pollution taxes[88]. Corporate Governance - The board of directors confirmed the authenticity, accuracy, and completeness of the semi-annual report[6]. - The company held one shareholders' meeting during the reporting period, which complied with legal regulations[73]. - The company appointed Dou Yaqi as the new General Manager and elected Jiang Tao and Pu Jian as non-employee supervisors[75]. - The company is committed to improving its governance structure and investor protection mechanisms, ensuring compliance in information disclosure and enhancing shareholder returns[49]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 57,368[104]. - The largest shareholder, Dou Qiling, holds 185,457,636 shares, representing 23.42% of the total shares[107]. - No significant changes in share capital structure occurred during the reporting period[103]. - The company did not propose any profit distribution or capital reserve transfer plan for the half-year period[76]. Investment and Subsidiaries - The company has fully consolidated all subsidiaries under its control, with a total investment of 53,341.39 million CNY in Hainan Chang'an International Pharmaceutical Co., Ltd., representing a 100% ownership stake[159]. - The company has established a wholly-owned subsidiary, Guizhou Yibai Traditional Chinese Medicine Granule Pharmaceutical Co., Ltd., to accelerate the production of traditional Chinese medicine granules[45]. - The company has not disclosed any new strategic investments or acquisitions in the reporting period[102][111]. Financial Management - The company is implementing a comprehensive budget management system and enhancing its information technology infrastructure to improve operational efficiency and management quality[47]. - The company reported a total investment of RMB 60.3 million in the Meian Technology New City new factory project, with cumulative actual investment reaching RMB 355 million[64]. - The company has ongoing investments in long-term assets, with fixed assets valued at CNY 1,200,315,539.63, up from CNY 1,175,796,158.13, an increase of about 2.09%[118].